CV Therapeutics^® is a biopharmaceutical company primarily focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. We apply advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery.

	More News
+ Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics + CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year + CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350

	Learn More
CV Therapeutics is looking for talented professionals to work in a rapidly growing, results-oriented, progressive research and development environment...